eFFECTOR Therapeutics
Founded Year
2012Stage
Acq - Pending | AcquiredTotal Raised
$139.6MAbout eFFECTOR Therapeutics
eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's approach provides a real opportunity to bring new medicines to patients in need.
Missing: eFFECTOR Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: eFFECTOR Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing eFFECTOR Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
eFFECTOR Therapeutics is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
838 items
eFFECTOR Therapeutics Patents
eFFECTOR Therapeutics has filed 33 patents.
The 3 most popular patent topics include:
- Transcription factors
- Gene expression
- Experimental cancer drugs
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/28/2020 | 9/13/2022 | Gene expression, Molecular biology, RNA, Protein biosynthesis, Ribosomal proteins | Grant |
Application Date | 2/28/2020 |
|---|---|
Grant Date | 9/13/2022 |
Title | |
Related Topics | Gene expression, Molecular biology, RNA, Protein biosynthesis, Ribosomal proteins |
Status | Grant |
Latest eFFECTOR Therapeutics News
Jan 6, 2023
Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated...
eFFECTOR Therapeutics Frequently Asked Questions (FAQ)
When was eFFECTOR Therapeutics founded?
eFFECTOR Therapeutics was founded in 2012.
Where is eFFECTOR Therapeutics's headquarters?
eFFECTOR Therapeutics's headquarters is located at 11180 Roselle Street, San Diego.
What is eFFECTOR Therapeutics's latest funding round?
eFFECTOR Therapeutics's latest funding round is Acq - Pending.
How much did eFFECTOR Therapeutics raise?
eFFECTOR Therapeutics raised a total of $139.6M.
Who are the investors of eFFECTOR Therapeutics?
Investors of eFFECTOR Therapeutics include Locust Walk Acquisition, Abingworth, Astellas Venture Management, Novartis Venture Funds, U.S. Venture Partners and 12 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.